Lysine BioTech Pvt.Ltd.

S.No	1.Small molecules based drugs delivery (IND)	Discovery stage and Early process development	Preclinical	Clinical trials
1	LB101 Efficacy and Safety of Kilirag-1 GLP-1”, “Type 2 Diabetes”, “Obesity”, “2 mg”, “once every 8 days” (IND)	50% Complete		2027
2	LB102 Efficacy and Safety of Kpondin1 (Spondin-1)- Medicines for Alzheimer's (IND)	50% Complete		2028

-->

S.No	2.Generations of CAR T-Cells	Discovery stage and Early process development	Preclinical	Clinical trials
1	LB201 Commercial Development of a Next-Generation huAnti-CAR19T-CD27/4-1BB-CD3ζ Therapy: Optimizing Clinical Efficacy and Safety	50% Complete		2027
2	LB202 Development of a Novel Humanized Anti-FAP CAR-T Cell Therapy Incorporating CD27 and CD3ζ Signaling Domains: Advancing Efficacy and Safety	50% Complete		2029
3	LB203 A Next-Generation Allogenic hup53-Directed CAR-T Cell Therapy with CD27–4-1BB–CD3ζ Costimulation for Improved Clinical Performance	50% Complete		2029
4	LB204 Commercial Development of Novel Anti-GD2 CAR-T Cells Incorporating CD27-4-1BB-NFAT-CD3ζ Signaling Domains for Improved Safety and Efficacy	50% Complete		2029
5	LB205 Advancing BCMA-Targeted CAR-T Cell Therapy: Novel huAnti-BCMA CAR Design with CD27–4-1BB–NFAT–CD3ζ Signaling for Improved Clinical Outcomes	50% Complete		2028
6	LB206 Development of a Novel Bi-cistronic huAnti-GPRC5D-hCD3 CAR-T Cell Platform Using Ribosomal Skipping to Integrate CD27, CD28, 4-1BB, and NFAT-CD3ζ Signaling for Improved Therapeutic Efficacy and Safety	50% Complete		2029
7	LB207 Development of a Bi-cistronic Anti-CD19/CD20 CAR-T Cell Therapy Using Ribosomal Skipping Integration of CD27/CD28/4-1BB/NFAT/CD3ζ Signaling Modules for Optimized Efficacy and Safety	50% Complete		2028
8	LB208 Development of Commercial Novel Tri-cistronic huanti-CD19-20-22 CART-CD27-CD28-41BB-NFAT-CD3ζ Cells Therapy Using Ribosomal Skipping: Towards Enhanced Efficacy and Safety	50% Complete		2028

-->

S.No	3.Adeno-Associated Virus (AAV) serotypes (AAV2–AAV9) and their roles in gene therapy:	Discovery stage and Early process development	Preclinical	Clinical trials
1	LB301 An AAV-based gene therapy designed to deliver a functional copy of dystrophin (DMD) mRNA for treating Duchenne muscular dystrophy (DMD).	50% Complete		2028
2	LB302 An AAV-SMN1 Gene Therapy Delivering Functional SMN1 mRNA for Spinal Muscular Atrophy — Towards Enhanced Efficacy and Safety.	50% Complete		2028

-->

S.No	4.messenger RNA (mRNA) vaccine that uses lipid nanoparticles (LNPs) as a delivery system to safely transport the fragile mRNA molecules into human cells	Discovery stage and Early process development	Preclinical	Clinical trials
1	LB401 Development of a Safe, Efficient, and Dual-Use LNP-Based mRNA Vaccine Targeting the Rabies Virus Glycoprotein (RABV-G) for Human and Veterinary Applications	50% Complete		2028
2	LB402 Development of a Safe, Efficient, LNP-Based mRNA Vaccine for Humans Against Leptospirosis.	50% Complete		2028